Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 168134, 9 pages
Research Article

Intravenous Laser Blood Irradiation Increases Efficacy of Etanercept in Selected Subtypes of Juvenile Idiopathic Arthritis: An Innovative Clinical Research Approach

1“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine, 16 Universitatii Street, 700115 Iasi, Romania
2Stronach Research Unit for Complementary and Integrative Laser Medicine, Research Unit of Biomedical Engineering in Anesthesia and Intensive Care Medicine, and TCM Research Center Graz, Medical University Graz, Auenbruggerplatz 29, 8036 Graz, Austria
3Institute for Laser Therapy and Acupuncture, Sohnreystraße 6, 37697 Lauenförde, Germany
4Department of Medical Physics, “Alexandru Ioan Cuza” University, 11 Carol I Boulevard, 700506 Iasi, Romania
5Laser Clinic, 83 Arcu Street, 700135 Iasi, Romania
6St. Mary Emergency Hospital for Children, Second Pediatric Clinic, 62 Vasile Lupu Street, 700309 Iasi, Romania

Received 3 July 2013; Accepted 13 July 2013

Academic Editor: Lu Wang

Copyright © 2013 Dragos Andrei Chiran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This single-blind, placebo-controlled study assesses the efficacy of synergic administration of intravenous laser blood irradiation (ILBI) and etanercept in selected subtypes of juvenile idiopathic arthritis (JIA). Etanercept is a tumor necrosis factor alpha blocking agent with recognized importance in JIA. Laser radiation has immunomodulatory effects in animal and human studies. Fourteen patients (Group I) received ILBI and 9 patients (Group II) received placebo laser. ILBI was performed in addition to ongoing JIA medication, including etanercept. ILBI was administrated in 3 sets of 5 consecutive daily sessions, with a 7-week interval between every set of sessions. Evaluation was performed using ACR (American College of Rheumatology) Pediatric Criteria (ACR Pedi) at study enrollment and at 10 and 20 weeks, respectively. After 10 weeks, 85.7% of the patients in Group I fulfilled Pedi 30 criteria, compared to only 55.6% of the patients in Group II. After 20 weeks, all patients in both groups had a Pedi 30 response. In Group I, 92.8% of the subjects met the Pedi 50 response, compared to only 55.6% in the placebo group. One patient in Group I responded best, fulfilling Pedi 70 criteria. If applied synergistically, ILBI and etanercept would have an increased efficacy in promoting JIA remission.